{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036995","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.298203+00:00","generated_at":"2026-05-31T09:41:11.870999+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuwellis Q2 revenue up 6% to $2.2M; gross margin expands to 67.2%","bullets":["Revenue $2.2M (+6% YoY); Critical Care revenue up 28%, Heart Failure consumables utilization up 35%.","Gross margin 67.2% vs 55.3% prior year; total operating expenses down 38% to $3.8M.","Net loss $7.7M vs $4.8M; basic EPS loss $18.85 vs $127.65 (improved due to share count changes).","Cash and equivalents $1.0M; no debt; closed registered direct offering for $2.0M gross proceeds on July 25.","Expanded Aquadex to pediatric patients in Florida hospital network; signed purchase agreement with 50-hospital Texas network."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036995","json":"https://secwatch.observer/filing/0001140361-24-036995.json","markdown":"https://secwatch.observer/filing/0001140361-24-036995.md","text":"https://secwatch.observer/filing/0001140361-24-036995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124036995/0001140361-24-036995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124036995/ef20033985_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:41:11.870999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}